Literature DB >> 30813924

Natural killer group 2D receptor and its ligands in cancer immune escape.

Shixin Duan1,2,3, Weihua Guo1,2,3, Zuxing Xu2, Yunbo He2, Chuting Liang2, Yongzhen Mo2, Yian Wang2, Fang Xiong2, Can Guo2, Yong Li2,4, Xiaoling Li2, Guiyuan Li1,2,3, Zhaoyang Zeng1,2,3, Wei Xiong5,6,7, Fuyan Wang8,9.   

Abstract

The immune system plays important roles in tumor development. According to the immune-editing theory, immune escape is the key to tumor survival, and exploring the mechanisms of tumor immune escape can provide a new basis for the treatment of tumors. In this review, we describe the mechanisms of natural killer group 2D (NKG2D) receptor and NKG2D ligand (NKG2DL) in tumor immune responses.Natural killer (NK) cells are important cytotoxic cells in the immune system, and the activated NKG2D receptor on the NK cell surface can bind to NKG2DL expressed in tumor cells, enabling NK cells to activate and kill tumor cells. However, tumors can escape the immune clearance mediated by NKG2D receptor/NKG2DL through various mechanisms. The expression of NKG2D receptor on NK cells can be regulated by cells, molecules, and hypoxia in the tumor microenvironment. Tumor cells regulate the expression of NKG2DL at the level of transcription, translation, and post-translation and thereby escape recognition by NK cells. In particular, viruses and hormones have special mechanisms to affect the expression of NKG2D receptor and NKG2DL. Therefore, NKG2D\NKG2DL may have applications as targets for more effective antitumor therapy.

Entities:  

Keywords:  Natural killer cell; Natural killer group 2D ligand; Natural killer group 2D receptor; Tumor; Tumor escape; Tumor microenvironment

Mesh:

Substances:

Year:  2019        PMID: 30813924      PMCID: PMC6391774          DOI: 10.1186/s12943-019-0956-8

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  54 in total

1.  The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.

Authors:  Massimo Fantini; Justin M David; Christina M Annunziata; Maria Pia Morelli; Phillip M Arlen; Kwong Y Tsang
Journal:  Cancer Biother Radiopharm       Date:  2020-01-13       Impact factor: 3.099

Review 2.  Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.

Authors:  Daixi Ren; Yuze Hua; Boyao Yu; Xin Ye; Ziheng He; Chunwei Li; Jie Wang; Yongzhen Mo; Xiaoxu Wei; Yunhua Chen; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2020-01-30       Impact factor: 27.401

Review 3.  Role of NKG2D and its ligands in cancer immunotherapy.

Authors:  Huifang Liu; Sijia Wang; Jing Xin; Jing Wang; Cuiping Yao; Zhenxi Zhang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

4.  B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis.

Authors:  Huimin Lu; Yanchao Ma; Mingyuan Wang; Jin Shen; Hongya Wu; Juntao Li; Nan Gao; Yanzheng Gu; Xueguang Zhang; Guangbo Zhang; Tongguo Shi; Weichang Chen
Journal:  Cancer Immunol Immunother       Date:  2020-10-29       Impact factor: 6.968

Review 5.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

Review 6.  An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks.

Authors:  Tshering D Lama-Sherpa; Lalita A Shevde
Journal:  Mol Cancer Res       Date:  2019-11-01       Impact factor: 5.852

Review 7.  AFAP1-AS1: a rising star among oncogenic long non-coding RNAs.

Authors:  Fang Xiong; Kunjie Zhu; Su Deng; Hongbin Huang; Liting Yang; Zhaojian Gong; Lei Shi; Yi He; Yanyan Tang; Qianjin Liao; Jianjun Yu; Xiaoling Li; Yong Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong; Shanshan Zhang; Can Guo
Journal:  Sci China Life Sci       Date:  2021-05-13       Impact factor: 6.038

8.  Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents.

Authors:  Burak Kucuk; Esra Yilmaz; Ercan Cacan
Journal:  Mol Biol Rep       Date:  2021-05-19       Impact factor: 2.316

9.  Downregulation of NKG2DLs by TGF-β in human lung cancer cells.

Authors:  Young Shin Lee; Hojung Choi; Hae-Ryung Cho; Woo-Chang Son; You-Soo Park; Chi-Dug Kang; Jaeho Bae
Journal:  BMC Immunol       Date:  2021-07-12       Impact factor: 3.615

Review 10.  Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.

Authors:  Alessandro Granito; Sara Marinelli; Antonella Forgione; Matteo Renzulli; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  J Hepatocell Carcinoma       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.